Goodwin Procter advised STALICLA on the deal.STALICLA announced its worldwide in-licensing of SFX-01, a patented composition of synthetic sulforaphane and alpha-cyclodextrin, from Evgen Pharma in neurodevelopmental disorders…
STALICLA’s In-licensing of SFX-01
